Accessibility Menu
BioCorRx logo

BioCorRx(OTC) BICX

Current Price$0.30
Market Cap$7.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-92%
5 Year-94%
1 Year-34%
1 Month-24%
BioCorRx last closing stock price
MetricPriceDate
Last closeUSD 0.252026-07-20
BioCorRx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-19.61%USD 0.312026-07-13
1 month-24.24%USD 0.332026-06-18
3 month-38.51%USD 0.412026-04-21
Year to date-14.12%USD 0.292025-12-31
1 year-34.21%USD 0.382025-07-18
3 year-87.75%USD 2.042023-07-21
5 year-93.75%USD 4.002021-07-21
Since inception-91.67%USD 3.002011-11-01

BioCorRx Financials at a Glance

Market Cap

$7.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$876.88K

Net Income (TTM)

-$3.43M

EPS (TTM)

-$0.32

P/E Ratio

-0.78

Dividend

$0.00

Beta (Volatility)

0.28 (Low)

Price

$0.30

Volume

283

Open

$0.30

Previous Close

$0.25

Daily Range

$0.30 - $0.30

52-Week Range

$0.20 - $1.28

Estimated Earnings Date

Aug 17, 2026

BICX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioCorRx

BioCorRx helps people manage addiction and weight issues with medical programs. Its products support those struggling with substance use or unhealthy eating. The company partners with clinics and doctors to deliver these solutions.

Products and Services

  • Addiction Treatment Programs: Medication-assisted recovery for opioid and alcohol use, including naltrexone implants and counseling (less than 1% of 2025 revenue).
  • Lucemyra Distribution: Supplies Lucemyra, a prescription drug for opioid withdrawal, to healthcare providers (99.8% of 2025 revenue).
  • Weight Management: UnCraveRx program combines medication and virtual support for weight loss (minimal 2025 revenue).
  • Research and Development: Develops new naltrexone-based treatments for substance use disorders, funded by government grants.

Growth and Expansion

  • Acquired Lucemyra assets from US WorldMeds in March 2025, expanding into opioid withdrawal treatment.
  • Secured $11 million NIH/NIDA grant in March 2024 for new drug research.
  • Entered new sales and distribution agreements in 2025 to grow Lucemyra reach.
  • Raised $1.9 million in equity financing in 2025 to support operations.

What Makes BioCorRx Stand Out

BioCorRx combines medication, behavioral therapy, and peer support in its addiction programs. The company relies on partnerships and licensing to reach clinics and healthcare providers. Government grants help fund research, reducing dependence on product sales.

Five Things You Need to Know

  • Revenue was $797,244 in 2025, up 10,301.1% from 2024.
  • 99.8% of 2025 revenue came from Lucemyra distribution.
  • Grant income was $2.4 million in 2025, up 65.4% from 2024.
  • Operating expenses rose 9.7% to $5.6 million in 2025.
  • Two customers accounted for all product revenue in 2025.

Bottom Line

BioCorRx has shifted focus to drug distribution and research funding. The company remains reliant on a few customers and external capital for growth.

AI Generated • Apr 16, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

CEO

Lourdes Felix, MBA

Website

www.biocorrx.com

Headquarters

Anaheim, CA 92806, US

BICX Financials

Key Financial Metrics (TTM)

Gross Margin

83.96%

Operating Margin

-552.33%

Net Income Margin

-391.15%

Return on Equity

28.12%

Return on Capital

N/A

Return on Assets

-147.53%

Earnings Yield

-1.28%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

29.06M

Volume

283

Avg. Volume

2.81K

Financials (TTM)

Gross Profit

$736.19K

Operating Income

-$4.84M

EBITDA

-$2.96M

Operating Cash Flow

-$2.04M

Capital Expenditure

$0.00

Free Cash Flow

-$2.04M

Cash & ST Invst.

$211.91K

Total Debt

$2.12M

BioCorRx Performance Analysis

BioCorRx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 213,841343.0%
20232023-12-31USD 89,160-58.3%
20242024-12-31USD 7,665-91.4%
20252025-12-31USD 797,24410301.1%
BioCorRx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3032.1%
Q32025-09-30256.4%
Q42025-12-31-123.8%
Q12026-03-31242.0%
BioCorRx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.61-25.4%
20232023-12-31USD -0.45-25.6%
20242024-12-31USD -0.498.1%
20252025-12-31USD -0.19-61.9%
BioCorRx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-30.2%
Q32025-09-30-51.7%
Q42025-12-31143.8%
Q12026-03-31-167.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$214.54K

+59.0%

Gross Profit

$167.64K

+24.3%

Gross Margin

78.14%

N/A

Market Cap

$7.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.42M

N/A

Employees

3

N/A

Net Income

-$831.23K

+1.2%

EBITDA

-$927.91K

-130.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$211.91K

+777.8%

Total Debt

$2.12M

-22.9%

Accounts Receivable

$452.07K

+23.7%

Inventory

$143.43K

+7.4%

Long Term Debt

$173.50K

-20.9%

Short Term Debt

$1.94M

-23.1%

Return on Assets

-1.48%

N/A

Return on Invested Capital

78.09%

N/A

Free Cash Flow

-$432.97K

+37.2%

Operating Cash Flow

-$432.97K

+37.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HLYKHealthLynked Corp.
$2.75+1.85%
FAMDFFutura Medical plc
$0.02+76.64%
PCLOFPharmaCielo Ltd.
$0.05+14.63%
XCRTXcelerate Inc.
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.41-0.05%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$44.32+0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$32.26-0.12%
TAT&T
$23.63+0.03%

Questions About BICX

What is the current price of BioCorRx?

BioCorRx is trading at $0.30 per share.

What is the 52-week range for BioCorRx?

Over the past 52 weeks, BioCorRx has traded between $0.20 and $1.28.

How much debt does BioCorRx have?

As of the most recent reporting period, BioCorRx reported total debt of $7.40M.

How much cash does BioCorRx have on hand?

BioCorRx reported $211.91K in cash and cash equivalents in its most recent financial results.

What is BioCorRx’s dividend yield?

BioCorRx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services